This article was originally published in The Tan Sheet
Sine-Off is the "first and only brand" of cough, cold, flu and sinus medicine to "completely remove pseudoephedrine from all of its products - not only nasal decongestants," Hogil Pharmaceutical announces Dec. 7. The line, which is now reformulated with phenylephrine, includes Sinus & Cold, Multi-Symptomand Sinus Painand iscurrently available in major mass retailers and drugstores nationwide. In addition, Hogil and its Sine-Off Charitable Foundation will provide an unrestricted educational grant to the Partnership for a Drug-Free America to support anti-meth measures, the firm announces. The firm will donate a percentage of sales from Sine-Off products to local anti-drug charities as well...
You may also be interested in...
Ads for reformulated Sine-Off cold and sinus products are scripted to position the brand as an active contributor to the nation's fight against methamphetamine abuse
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.